253:
230:
477:
31:
322:
336:
364:
InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
518:
567:
537:
356:
67:
43:
395:
169:
572:
209:
435:"Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis"
552:
511:
383:
562:
248:
557:
198:
542:
504:
225:
84:
547:
391:
387:
456:
158:
93:
446:
265:
178:
252:
229:
488:
531:
241:
118:
484:
415:
451:
434:
298:
149:
22:
460:
476:
30:
129:
138:
104:
189:
321:
312:
433:
Muehler A, Peelen E, Kohlhof H, Gröppel M, Vitt D (August 2020).
214:
492:
344:
COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F
310:
297:
264:
259:
240:
208:
188:
168:
148:
128:
103:
83:
58:
42:
37:
117:
92:
512:
8:
21:
519:
505:
251:
228:
157:
75:2-carbamoyl]cyclopentene-1-carboxylic acid
29:
450:
177:
439:Multiple Sclerosis and Related Disorders
407:
361:
341:
224:
137:
72:
242:
20:
197:
7:
473:
471:
108:
14:
422:. Springer Nature Switzerland AG.
386:that is being evaluated to treat
475:
416:"Vidofludimus calcium - Immunic"
285:
282:
276:
369:Key:XPRDUGXOWVXZLL-UHFFFAOYSA-N
288:
270:
1:
491:. You can help Knowledge by
396:dihydroorotate dehydrogenase
452:10.1016/j.msard.2020.102129
589:
470:
260:Chemical and physical data
568:3-Methoxyphenyl compounds
352:
332:
63:
28:
538:Anti-inflammatory agents
384:investigational new drug
487:-related article is a
25:
573:Pharmacology stubs
392:ulcerative colitis
500:
499:
377:
376:
323:Interactive image
210:CompTox Dashboard
16:Chemical compound
580:
553:Carboxylic acids
521:
514:
507:
479:
472:
465:
464:
454:
430:
424:
423:
412:
325:
305:
290:
287:
284:
278:
272:
255:
244:
233:
232:
218:
216:
201:
181:
161:
141:
121:
111:
110:
96:
33:
26:
24:
588:
587:
583:
582:
581:
579:
578:
577:
528:
527:
526:
525:
469:
468:
432:
431:
427:
414:
413:
409:
404:
388:Crohn's disease
373:
370:
365:
360:
359:
348:
345:
340:
339:
328:
303:
293:
281:
275:
236:
212:
204:
184:
164:
144:
124:
107:
99:
79:
76:
71:
70:
54:
51:Investigational
17:
12:
11:
5:
586:
584:
576:
575:
570:
565:
563:Fluorobenzenes
560:
555:
550:
545:
540:
530:
529:
524:
523:
516:
509:
501:
498:
497:
480:
467:
466:
425:
406:
405:
403:
400:
375:
374:
372:
371:
368:
366:
363:
355:
354:
353:
350:
349:
347:
346:
343:
335:
334:
333:
330:
329:
327:
326:
318:
316:
308:
307:
301:
295:
294:
291:
279:
273:
268:
262:
261:
257:
256:
246:
238:
237:
235:
234:
226:DTXSID50431325
221:
219:
206:
205:
203:
202:
194:
192:
186:
185:
183:
182:
174:
172:
166:
165:
163:
162:
154:
152:
146:
145:
143:
142:
134:
132:
126:
125:
123:
122:
114:
112:
101:
100:
98:
97:
89:
87:
81:
80:
78:
77:
74:
66:
65:
64:
61:
60:
56:
55:
53:
52:
48:
46:
40:
39:
35:
34:
15:
13:
10:
9:
6:
4:
3:
2:
585:
574:
571:
569:
566:
564:
561:
559:
558:Cyclopentanes
556:
554:
551:
549:
546:
544:
541:
539:
536:
535:
533:
522:
517:
515:
510:
508:
503:
502:
496:
494:
490:
486:
481:
478:
474:
462:
458:
453:
448:
444:
440:
436:
429:
426:
421:
417:
411:
408:
401:
399:
397:
393:
389:
385:
381:
367:
362:
358:
351:
342:
338:
331:
324:
320:
319:
317:
314:
309:
302:
300:
296:
269:
267:
263:
258:
254:
250:
247:
245:
243:ECHA InfoCard
239:
231:
227:
223:
222:
220:
211:
207:
200:
196:
195:
193:
191:
187:
180:
176:
175:
173:
171:
167:
160:
156:
155:
153:
151:
147:
140:
136:
135:
133:
131:
127:
120:
116:
115:
113:
106:
102:
95:
91:
90:
88:
86:
82:
73:
69:
62:
57:
50:
49:
47:
45:
41:
36:
32:
27:
19:
543:Carboxamides
493:expanding it
485:pharmacology
482:
442:
438:
428:
419:
410:
380:Vidofludimus
379:
378:
199:ChEMBL197194
94:1034190-08-3
44:Legal status
38:Legal status
23:Vidofludimus
18:
420:AdisInsight
398:inhibitor.
306: g·mol
249:100.112.872
59:Identifiers
532:Categories
445:: 102129.
402:References
394:. It is a
311:3D model (
299:Molar mass
179:GHG2B47067
150:ChemSpider
85:CAS Number
68:IUPAC name
548:Biphenyls
461:32428844
130:DrugBank
304:355.365
266:Formula
159:7995757
139:DB15446
119:9820008
105:PubChem
459:
382:is an
337:SMILES
190:ChEMBL
483:This
357:InChI
313:JSmol
489:stub
457:PMID
390:and
170:UNII
447:doi
215:EPA
109:CID
534::
455:.
443:43
441:.
437:.
418:.
280:18
274:20
520:e
513:t
506:v
495:.
463:.
449::
315:)
292:4
289:O
286:N
283:F
277:H
271:C
217:)
213:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
